Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV3000-406: Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
2022-001175-14Phase 4Active
- Sponsor
- Biohaven Ltd.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Headache pain relief at 2 hours post-dose. Started Nov 2022; status: active.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2022-001175-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001175-14.